Real-World Outcomes of Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Cohort Study From Vietnam [0.03%]
Durvalumab巩固治疗联合放化疗后不可切除的III期非小细胞肺癌的真实世界结局：越南一项回顾性队列研究
Hau Thi Tran,Kien Hung Do,Huong T T Nguyen et al.
Hau Thi Tran et al.
Introduction: Durvalumab administered after definitive chemoradiotherapy has changed the treatment landscape for patients with unresectable stage III non-small cell lung cancer (NSCLC). Evidence describing treatment outco...
Contribution of Focal 1 8F-FDG Uptake on Positron Emission Tomography/Computed Tomography to Ultrasonography-Based Malignancy Risk Assessment in Incidentally Detected Thyroid Nodules [0.03%]
正电子发射断层扫描/计算机断层扫描 focal 1 8F-FDG摄取对偶然发现的甲状腺结节超声恶性风险评估的贡献度分析
Yusuf Öztürk,Buğra Kaya,Yusuf Karadeniz et al.
Yusuf Öztürk et al.
Aim: The present study sought to evaluate the incremental contribution of the presence of focal FDG uptake and SUVmax on PET/CT in predicting malignancy in incidentally detected thyroid nodules when assessed in conjunctio...
Evolving Trends in Laryngeal Cancer Mortality in the United States, 1999-2024: A Population-Based Analysis With Subgroup Stratified Trends through 2020 [0.03%]
1999-2024年美国喉癌死亡率的演变趋势：基于人口的分析及其在2020年的亚组分层趋势
Aryan Tareen,Anoud Khan,Saqib Raza Khan et al.
Aryan Tareen et al.
Background: Laryngeal cancer (LC) represents one-third of all head and neck cancers, with global deaths rising by 36.7% between 1990 and 2021. Although mortality has declined over the past two decades, recent data indicat...
Role of Tonsillectomy in Cervical Squamous Cell Carcinoma With Unknown Primary in Human Papillomavirus-Negative Patients: A Prospective Observational Study [0.03%]
负人类乳头瘤病毒不明原发部位扁桃体的喉癌患者行扁桃体切除术的作用：前瞻性观察研究
Prateek V Jain,Bibek Khanal,Vikram Kekatpure et al.
Prateek V Jain et al.
Introduction: Management of cervical squamous cell carcinoma with unknown primary (SCCUP) continues to evolve with emphasis on tonsillectomy for identification of the primary. While the data from an HPV positive populatio...
Healthcare Utilization and Out-of-Pocket Expenditure Among Adults With and Without Cancer in Korea-Analysis of the Korea Health Panel Survey [0.03%]
韩国成人癌症患者和非癌症患者的医疗利用及自付费用——基于韩国健康面板调查的分析
Durga Datta Chapagain,Vasuki Rajaguru,Do Hee Kim et al.
Durga Datta Chapagain et al.
Background: Cancer imposes substantial clinical and financial burdens worldwide. Although Korea operates a universal National Health Insurance system, concerns remain regarding healthcare utilization and out-of-pocket (OO...
Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia [0.03%]
达雷妥尤单抗治疗澳洲部分地区复发或难治性多发性骨髓瘤的疗效和安全性:基于登记数据库的事后研究分析
Benjamin Reardon,Ian Kerridge,Tasman Armytage
Benjamin Reardon
Daratumumab is widely used for relapsed or refractory multiple myeloma, yet outcomes from regional Australian centers remain underreported. This retrospective study evaluated real-world treatment patterns between 2018 and 2023 and survival ...
Established Prognostic Scores Predict Screen Failure But Not Post-Enrollment Outcomes in Phase 1 Oncology Trials: A Single Centre Retrospective Audit [0.03%]
一项单中心回顾性审核： established预后评分能够预测筛选失败，但不能预测一期临床试验中患者的入组后的结果
Ortis Estacio,Eve Malsem,Georgia McGuiness et al.
Ortis Estacio et al.
Background: Real-world safety and outcome data from Phase 1 trial populations-including screen failures-remain limited. We conducted a retrospective audit to evaluate the predictive utility of established Phase 1 prognost...
The Importance of Driver-Targeted Therapy Among Patients With Lung Cancer Initially Diagnosed in the Intensive Care Unit [0.03%]
重症监护病房初诊肺癌患者的驱动基因导向治疗的重要性
Yi-Chun Hsiao,Wei-Fan Ou,Po-Hsin Lee et al.
Yi-Chun Hsiao et al.
Background: Patients who had been diagnosed with lung cancer during intensive care unit (ICU) admission showed poor prognosis. This research investigated the clinical characteristics related to the outcomes of these patie...
Efficacy and Safety of Two-Weekly Enfortumab Vedotin in Combination With Pembrolizumab for Advanced Urothelial Carcinoma [0.03%]
替雷利珠单抗联合贝伐珠单抗治疗尿路上皮癌的疗效和安全性：一项II期研究
Ryunosuke Nakagawa,Kouji Izumi,Kazuki Toshima et al.
Ryunosuke Nakagawa et al.
Introduction: Enfortumab vedotin (EV) plus pembrolizumab (PEM) is a standard first-line therapy for advanced urothelial carcinoma (UC), but EV-related toxicities frequently lead to treatment modification or discontinuatio...
Identification of Methionine Metabolism-Driven Heterogeneous Subtypes in Colorectal Cancer and Their Associated Immune Microenvironment [0.03%]
结直肠癌中异柠檬酸脱氢酶突变亚型的免疫微环境差异性分析
Junhao Zhou,Wanhua Deng,Manzhao Ouyang
Junhao Zhou
Aim: Tumor heterogeneity, driven by metabolic reprogramming, challenges colorectal cancer (CRC) treatment. Methionine metabolism is crucial for tumor progression, but its role in CRC heterogeneity and the tumor immune mic...